CROI 2010
CROI 2010: LEDGF/p75 Integrase Inhibitors and Capsid Assembly Inhibitors Offer New Approaches for Blocking HIV Replication
- Details
- Category: HIV Treatment
- Published on Tuesday, 02 March 2010 12:57
- Written by Liz Highleyman
While the drug development pipeline is not as full as it has been in recent years, researchers continue to work on new approaches to antiretroviral therapy. Two such novel approaches -- LEDGF integrase inhibitors and capsid assembly inhibitors -- were described in oral presentations at the recent 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) last month in San Francisco.
CROI 2010: ACTG 5202 Shows Abacavir/lamivudine and Tenofovir/emtricitabine Provide Similar HIV Suppression at Low Viral Loads
- Details
- Category: HIV Treatment
- Published on Tuesday, 02 March 2010 12:57
- Written by Liz Highleyman
Two widely used components of first-line combination antiretroviral therapy (ART) -- abacavir/lamivudine (Epzicom) and tenofovir/emtricitabine (Truvada) -- suppress HIV viral load about equally well when combined with either the NNRTI efavirenz (Sustiva) or the ritonavir-boosted protease inhibitor atazanavir (Reyataz) in people with low baseline viral loads, according to final results from the ACTG 5202 trial reported at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) last month in San Francisco.
CROI 2010: Moderate Liver Fibrosis Predicts Disease and Death in HIV/HCV Coinfected People, but Successful Treatment Appears Protective
- Details
- Category: Fibrosis & Cirrhosis
- Published on Friday, 26 February 2010 19:16
- Written by Liz Highleyman
Even moderate liver fibrosis (greater than stage F1) in HIV/HCV coinfected patients is associated with adverse clinical outcomes including liver cancer, liver failure, and death, investigators reported at the 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010) last week in San Francisco. However, effective HIV treatment producing long-term viral suppression and successful hepatitis C treatment leading to sustained virological response appeared to be protective.
CROI 2010: Abacavir (Ziagen) Does Not Compromise Effectiveness of Hepatitis C Treatment, but Zidovudine (Retrovir) May Reduce Response
- Details
- Category: HIV/AIDS
- Published on Tuesday, 02 March 2010 12:57
- Written by Liz Highleyman
Using a nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) backbone containing abacavir (Ziagen, also in the Epzicom coformulation) was not associated with poorer response to interferon-based therapy for hepatitis C in HIV/HCV coinfected patients, researchers reported at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) last month in San Francisco. However, backbones containing zidovudine (AZT; Retrovir) and possibly didanosine (ddI; Videx) were associated with a lower likelihood of achieving a sustained response.
CROI 2010: Quitting Smoking Lowers Risk of Cardiovascular Disease in People with HIV
- Details
- Category: Cardiovascular Disease
- Published on Friday, 26 February 2010 12:57
- Written by Liz Highleyman
Cigarette smoking was associated with a significantly higher rate of cardiovascular disease among people with HIV, but the risk began to decline after quitting and continued to fall over time, researchers reported at the 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010) last week in San Francisco. A similar pattern was not seen for overall mortality, however.
More Articles...
- CROI 2010: HIV Raises Lung Cancer Risk, but Smoking Is a Much Stronger Predictor
- CROI 2010: Leakage of Gut Bacteria Linked to Poor Hepatitis C Treatment Response in HIV/HCV Coinfected Patients
- CROI 2010: Investigational Drug TBR-652 Demonstrates Dual Activity against CCR5 and CCR2 Co-receptors
- CROI 2010: Treatment Intensification with Maraviroc (Selzentry) Did Not Raise CD4 Cell Counts in Small Study
Web Design and Development by